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Background. Similar to tissue stem cells, primitive tumor cells in chronic myelogenous leukemia have been observed to
undergo quiescence; that is, the cells can temporarily stop dividing. Using mathematical models, we investigate the effect of
cellular quiescence on the outcome of therapy with targeted small molecule inhibitors. Methods and Results. According to
the models, the initiation of treatment can result in different patterns of tumor cell decline: a biphasic decline, a one-phase
decline, and a reverse biphasic decline. A biphasic decline involves a fast initial phase (which roughly corresponds to the
eradication of cycling cells by the drug), followed by a second and slower phase of exponential decline (corresponding to
awakening and death of quiescent cells), which helps explain clinical data. We define the time when the switch to the second
phase occurs, and identify parameters that determine whether therapy can drive the tumor extinct in a reasonable period of
time or not. We further ask how cellular quiescence affects the evolution of drug resistance. We find that it has no effect on the
probability that resistant mutants exist before therapy if treatment occurs with a single drug, but that quiescence increases the
probability of having resistant mutants if patients are treated with a combination of two or more drugs with different targets.
Interestingly, while quiescence prolongs the time until therapy reduces the number of cells to low levels or extinction, the
therapy phase is irrelevant for the evolution of drug resistant mutants. If treatment fails as a result of resistance, the mutants
will have evolved during the tumor growth phase, before the start of therapy. Thus, prevention of resistance is not promoted
by reducing the quiescent cell population during therapy (e.g., by a combination of cell activation and drug-mediated killing).
Conclusions. The mathematical models provide insights into the effect of quiescence on the basic kinetics of the response to
targeted treatment of CML. They identify determinants of success in the absence of drug resistant mutants, and elucidate how
quiescence influences the emergence of drug resistant mutants.
Citation: Komarova NL, Wodarz D (2007) Effect of Cellular Quiescence on the Success of Targeted CML Therapy. PLoS ONE 2(10): e990. doi:10.1371/
journal.pone.0000990
INTRODUCTION
Cellular quiescence is a central process that regulates the kinetics
of cellular proliferation and tissue homeostasis, especially in stem
cells [1–6]. If stem cells are not needed to divide and to replenish
tissue cells, they temporarily stop to progress through the cell cycle
until further divisions are required. Several cancers are thought to
be maintained by ‘‘cancer stem cells’’ in a similar manner as
healthy tissue is maintained by regular stem cells [7–10]. That is,
the primitive cells divide and give rise to cells that are
differentiated to a certain degree, at least during the earlier stages
of the disease. Cancer stem cells are thought to be an important
target for any therapy that aims to eradicate the tumor [11,12] . If
the stem cells are not eliminated, the cancer is likely to relapse
[13]. While primitive cancer cells proliferate with a higher rate
than healthy cells, data indicate that they can still undergo
quiescence, both during tumor growth and during treatment . An
example of where this has been demonstrated is chronic
myelognous leukemia (CML) [14,15]. It is even possible that in
this case, therapy induces quiescence in primitive cancer cells [16].
Quiescent cells in turn are not affected by the drug and are
therefore shielded from therapy-induced elimination [16].
Chronic myelogenous leukemia (CML) is a cancer of the
hematopoietic system which progresses in three phases: the chronic
phase, the accelerated phase, and blast crisis [17–20]. It is thought
that cell growth is brought about by the proliferation of cancerous
stem cells and progenitor cells [21]. During the chronic phase of the
disease, the fraction of immature cells is relatively low, while a sharp
increase in the fraction of immature cells is observed as the disease
progresses. It is thought that CML initiation and progression is
driven by the product of the BCR-ABL fusion gene (Philadelphia
chromosome) [17]. The BCR-ABL protein has a constitutively
activated tyrosine kinase, activating multiple signal transduction
pathways. This leads to excessive cellular proliferation, reduced
apoptosis, and decreased cellular adhesion. Imatinib mesylate
(STI571 or Gleevec) is a targeted inhibitor of the BCR-ABL fusion
protein and has given rise to impressive treatment results, especially
when treatment is started during the chroninc phase of the disease
[20,22–28]. Blood cell counts return to normal levels, and the levels
of the BCR-ABL gene can even become undetectable. While
patients tend to relapse after cessation of Imatinib treatment [29–
32], a recent study has shown that some patients did not show any
relapse as long as two years after treatment cessation, raising the
possibility that CML has been eradicated from these patients [33].
There are two major barriers to CML eradication by Imatinib.
First, not all cells in the heterogeneous CML population are
equally susceptible to treatment. The problem lies especially with
the population of stem cells. While some have argued that stem
cells are not at all susceptible to Imatinib [30], another scenario is
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but are not affected by the drugs while in a quiescent state
[13,16,29]. Because primitive CML cells have been observed to
undergo quiescence, and because Imatinib itself might trigger
a quiescent state in some cells, tumor eradication can be a difficult
task. Second, the tumor cells can evolve acquired resistance to
Imatinib [22,23,25,27,28,34–40]. This can be conferred by point
mutations or gene amplification events. The probability that
a resistant cell is generated in turn depends on the growth kinetics
of the cancer cell population, which are influenced by regulatory
processes such as quiescence and cell death.
This paper investigates how cellular quiescence influences the
kinetics of the treatment response, and the probability of treatment
failure as a result of acquired resistance. Initiation of therapy can
result in three patterns of tumor cell decline in the model. In one
parameter region, we first observe a fast phase of tumor cell decline
(roughly corresponding to the eradication of cycling cells by the
drug), followed by a slower phase (awakening and death of quiescent
cells), a pattern which has been observed in clinical data [29,30]. For
this case, we define mathematically the time when the switch to the
second and slower phase occurs. The other two patterns of tumor
cell decline are a one-phase decline and a reverse biphasic decline.
Eventually, the model predicts the extinction of the CML cells, and
defines the time when extinction occurs. Depending on the
parameter values, this may or may not occur in a realistic period
of time. The calculations therefore define conditions under which
imatinib therapy fails to eradicate the cancer, and when eradication
can be successful. A more elaborate model includes the ability of
tumor cells to acquire mutations that confer drug resistance. We find
that in the context of treatment with a single drug, parameters that
determine the kinetics of cellular quiescence do not affect the
probability of treatment failure as a result of drug resistant mutants.
On the other hand, if two or more drugs are used in combination to
treatthecancer,thentreatmentfailureasaresultofdrugresistanceis
promoted by the occurrence of cellular quiescence. Interestingly,
while cellular quiescence significantly prolongs the time until the
cancer has dropped to low numbers or has been driven extinct, the
model predicts that drug resistance does not evolve during this
treatment phase in this case. Increased cellular quiescence increases
the likelihood that resistant mutantsare generated during the growth
phase of the cancer before therapy is initiated.
RESULTS
Treatment in the absence of drug resistant mutant
cells
We formulate a stochastic model that includes a population of
primitive, proliferating CML cells, and a population of quiescent
CML cells. The proliferating cells divide with a rate l and die with
a rate d. The death rate captures both the natural death rate of
cancer cells and the treatment-induced death rate. In the absence
of treatment, l.d, and the cell population grows exponentially.
Treatment increases the parameter d. If treatment is efficient, then
l,d, such that the tumor cell population declines. The cells enter
a quiescent state with a rate a, and quiescent cells re-enter the cell
cycle with a rate b. Note that quiescent cells do not divide or die
and are not susceptible to any drug activity. We first consider the
average numbers of proliferating and quiescent cells, x(t) and y(t),
as a function of time. This can be described by the following pair
of ordinary differential equations:
_ x x~(l{d{a)xzby,
_ y y~ax{by:
Note, that this model does not explicitly take into account
differentiated CML cells. These are not thought to contribute
significantly to malignant growth and are simply proportional to
the number of primitive CML cells.
Assume the existence of a number of primitive CML cells,
a fraction of which is quiescent. They are treated with the drug
imatinib. In this first model, we assume that all CML cells are
susceptible to the drug and that no drug resistance is generated by
mutation. In this scenario, the death rate of the CML cells is
greater than their division rate (d.l), such that the population of
cells declines. The model suggests various behaviors upon
initiation of treatment. In one parameter region, therapy results
in two distinct phases of exponential decline (Figure 1), as observed
in experimental data [29,30]. First, the population of cells declines
exponentially with a relatively fast rate, l-, as a result of the death
of proliferating cells, x. Then, a slower phase of exponential
decline at a rate l+ is observed because the quiescent cells become
dominant and are only killed when they wake up and re-enter
a cycling state. The values l6 are given by
l+~
1
2
d{lzazb+
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q   
: For small
values of a the expressions for the decay rates simplify and we have
l+=-(d-l) and l-=2b , that is, the first wave of decline happens at
the net decay rate of cycling cells and the second wave happens at
the rate of cell awakening.
In this model, treatment will eventually drive the tumor to
extinction, but the time it takes to achieve this goal is influenced by
the kinetics of the second, slower phase of decline, and thus by the
rate at which cells enter the quiescent state, and the rate at which
cells exit the quiescent state. The higher the rate at which cells
enter quiescence, and the slower the rate at which cells exit
quiescence, the longer it takes to reduce the CML population
towards extinction. Also, the lower the overall death rate of cells,
the longer it takes to reduce the tumor towards extinction. In the
model, the time of the switch between the two phases of decline
(Figure 1) is given proportional to
1
lz{l{ jj
, and the time of
extinction is proportional to
1
lz jj
(see supplementary information,
Text S1 Sections 1.2 and 1.3 for the exact expressions).
Figure 1. Biphasic decline of the CML cell population as a function of
time, for parameters l=1, d=1.5, a=0.01, b=0.2, I0=10
8 and
J0=10
2. The solid line represents log10(x(t)+y(t)), and the dashed lines
are log10(g+exp{l+t}) and log10(g-exp{l-t}) (See Text S1, Section 1.1 and
1.2 for details). The time of treatment in this case is Ttreat=72.1 and the
switching time is Tswitch=5.1.
doi:10.1371/journal.pone.0000990.g001
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model. This type of biphasic decline occurs if the death rate of cells
is larger than the sum of the division and quiescence rates
(d.l+a+b). For smaller death rates, when this condition is not
fulfilled, two further patterns of decline are observed. Either the
population of cells declines in a single exponential phase during
treatment, or a first and slower phase of cell decline is followed by
a second and faster phase of cell decline (a reverse biphasic
decline). Exact mathematical conditions for these parameter
regions are given in Text S1, Section 1.1. This behavior is
observed if there is more quiescence in the population of tumor
cells. In this case, the first phase need not be the fastest anymore,
because it can be dictated by the kinetics of cell activation rather
than cell death. Once a sufficient number of cells has been
activated, cell death is the dominant factor and the rate of cell
decline speeds up.
In order to show that our equations can accurately describe
clinical data, we fitted the model to two data sets that document
a bi-phasic decline of CML cells during treatment (Figure 2).
Details of the data fitting procedures are given in Text S1, Section
1.4. The first data set is taken from Michor et al [30] and contains
median BCR-ABL transcript levels from a selected cohort (n=68)
that excludes cases with transiently increasing BCR-ABL tran-
script levels (Figure 2a). The second data set is taken from Roeder
et al [29] and contains median BCR-ABL transcript levels from an
unselected cohort (n=69) of CML patients (Figure 2b). In addition
to the median values, Roeder et al presented individual responses
to imatinib therapy. Figure 3 re-plots the clinical data from two
patients that do not show a bi-phasic decline. Based on our model,
it can be hypothesized that in these patients the number of CML
cells declines in a single exponential phase during treatment
(Figure 3a), or according to the reverse biphasic decline pattern
(Figure 3b). However, analysis of additional data for longer periods
of time will be necessary to test this hypothesis.
We can also investigate the dynamics of CML decline during
treatment in stochastic terms rather than considering the average
behavior of the population of CML cells. That is, assuming that we
start with I0 cycling cells and J0 quiescent cells, we examine the
probability that the population of CML cells is extinct. This
probability increases monotonically with time and tends toward
one as time goes to infinity. We can calculate the time when the
probability of CML extinction approaches one. As expected,
a higher rate at which cells enter quiescence and a lower rate at
which cells exit quiescence increases the time until the probability
of tumor extinction converges to one.
In summary, whether or not CML can be cured by imatinib
therapy in the absence of acquired resistance depends on the time
it takes for the cancer cells to be driven extinct by the treatment,
and this in turn depends on the rate constants. Eventual CML
extinction is the only theoretically possible outcome in the
presence of therapy, but it may be achieved after a period of
time that is longer than the life-span of the patient. Variations in
parameters that determine the kinetics of cellular quiescence can
determine whether relapse is observed in patients that stop
imatinib treatment after a certain period of time [33]. Note that
our notion of treatment induced ‘‘cancer extinction’’ is a mathe-
matical one, that is, in the model we analyze here, the cancer cell
population goes extinct, which corresponds to a cure. In patients,
however, other complicating factors not included in this model
may render tumor extinction a difficult goal to achieve by
treatment. Therefore, our mathematical notion of ‘‘tumor
extinction’’ should be translated into ‘‘clinical remission’’ in
a medical context.
Quiescence and the generation of drug resistant
mutants
In the next, more complete model, CML cells can mutate to give
rise to acquired drug resistance. In particular, we assume that
during cell division, a resistant mutant is generated with
a probability u. We further assume that CML cells grow
exponentially to a defined size N, after which the disease is
Figure 2. The relative amount of CML cells as a fuction of time, in patients treated with Imatinib. The circles represent experimental data replotted
from (a) Michor et al [30] and (b) from Roeder et al [29]; they show the median values of BCR-ABL transcripts (relative to BCR transcripts in (a) and ABL
transcripts in (b)). The vertical bars are the quartiles. The solid lines represent the fitted theoretical curves, formula (7) of Text S1, obtained by a mean-
square procedure. The estimated parameter values are: (a) d-l=0.0502 days
21, b=0.0065 days
21, a=10
25 days
21,J 0=0.47; (b) d-l=0.0278 days
21,
b=0.0067 days
21, a=0.0004 days
21,J 0=0.50. Here J0 denotes the initial percentage of quiescent CML cells.
doi:10.1371/journal.pone.0000990.g002
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probability that the cancer is driven extinct by therapy, i.e. the
probability that no resistant mutants spread before the CML cells
have gone extinct. We examine how this probability depends on
the parameters that determine cellular growth, mutations,
quiescence and death. When talking about tumor extinction in
the model, we always imply extinction brought about by drug
therapy. As noted before, this should be thought of as ‘‘clinical
remission’’ in medical rather than mathematical terms.
A previous model studied the probability of treatment failure as
a result of drug resistance, but did not take into account cellular
quiescence [41]. There, the result was obtained that the treatment
phase is largely irrelevant for the generation of resistance. That is,
if treatment does fail because of drug resistant mutants, these
mutants were generated in the growth phase before the start of
therapy. Quiescence can significantly slow down the rate with
which the tumor cell population declines during treatment, thus
prolonging this phase. The argument has been made that the
tumor might acquire resistance during this phase and that this
could lead to a relapse of the tumor after a certain time, despite
continued therapy. We have performed a similar analysis with the
current model, and found that even in the presence of quiescence,
the treatment phase is not relevant for the generation of drug
resistant mutants, no matter how long treatment takes. Thus, if at
the start of therapy no resistant mutants exist, treatment is likely to
result in the extinction of the tumor, given enough time (see Text
S1 Section 2.2 for calculations).
With this in mind, we calculate the probability of treatment
success depending on the rate at which cells enter quiescence, a,
and the rate at which cells exit the quiescent state, b. Several
scenarios are considered. First we study resistance against a single
drug (i.e. imatinib in CML treatment). We then also take into
account resistance against 2 or more drugs used in combination.
This is relevant because in addition to imatinib, further drugs are
being developed that could be used in combination with imatinib
to treat CML [23,42]. In the main body of the paper we only
present intuitive arguments. The rigorous calculations are given in
Text S1 Section 2. Throughout the next few paragraphs we make
the simplifying assumption that the cell death rate in the pre-
treatment phase is zero. Also, the theoretical explanations will
concentrate on one of the quiescence parameters, a, which is the
rate of entering the state of quiescence. The rate of cell awakening,
b, can be treated similarly (see e.g. Text S1, Section 3.4). Figure 4
illustrates the a- and b- dependence of the probability of no
resistance. It was created by numerical solutions of ordinary
differential equations for the characteristics, see the theory of Text
S1, Section 2.3. The calculations give rise to the following findings.
Probability of one-drug treatment failure (due to
resistance) is independent of quiescence The probability
to observe treatment failure as a result of resistance in the context of
a singledrug is not affectedbyquiescence parameters(Figure 4a). To
put this in quantitative terms, the probability to have at least one
resistant mutant at size N is independent of a and b.
This is demonstrated by the following argument (see also Text
S1, Sections 3.2 and 3.3) . Let us assume for simplicity that there is
no cell death in the colony (all the arguments can be extended to
nonzero death rates). In the model, mutants are generated during
cell division. The probability of resistance is the same as the
probability to generate mutants, which is defined by the number of
cell divisions (and the constant mutation rate). It is easy to see that
the total number of cell divisions until the tumor reaches size N
does not depend on the quiescence parameters a and b. For
instance, if there is no cell death, then the number of cell divisions
to expand from one cell to N cells is exactly N-1, no matter what the
quiescence rates are, see Figure 5. It is of course the case that the
highertherateat which cellsenterquiescence,and the lowerthe rate
atwhichcellsexitquiescence,thelongerittakesthe tumorto growto
size N. However, the actual number of cell divisions to reach size N is
unchanged by quiescence. Therefore, the probability to produce
resistant mutants is independent of quiescence rates.
As we will see in the following paragraphs, the situation is
different when considering resistance against two or more drugs.
For treatment with multiple drugs, the probability of treatment
failure as a result of resistance depends on the quiescence
parameters (Figure 4b–d). The higher the rate of entry into the
quiescent state (larger a) and the lower the rate of exit from the
Figure 3. Data that document the decline of CML cells during imatinib treatment in two patients, taken from Roeder et al [29].
doi:10.1371/journal.pone.0000990.g003
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failure. In order to explain this, we will consider generating
resistance to two drugs; higher numbers of drugs can be treated
similarly. We build our arguments as follows.
The number of cycling 1-hit mutants is independent of the
quiescence parameters Cycling mutants are produced by
cycling wild-type cells and they grow according to the same law as
the cells producing them. When a increases (or b decreases), the
mutant clones grow more slowly because of quiescence, but at the
same time they have more time to grow, see Figure 6. In other
words, the changes in the mutant growth are completely
compensated by the change in the time of growth. Therefore,
we conclude that the number of cycling 1-hit mutants in a colony
of a given size is also independent of quiescence.
The more quiescence there is in the colony, the larger is
the total number of quiescent wild-type cells This result is
actually a consequence of a more general statement, that for each
cell type (that is, cells resistant to 0, 1, 2 etc drugs), the number of
quiescent cells divided by the number of cycling cells is given by a/
(l2a) (see Text S1, Section 3.2). The particular fact that we will
need is that, up to a small correction, the number of quiescent
wild-type cells in a colony of size N is given by aN/l, whereas the
number of cycling wild-type cells is given by (1-a/l)N (here we
assume that the mutation rate is small compared to 1, which is
a safe bet).
The probability of two-drug treatment failure (due to
resistance) increases with the quiescence rate Our
calculations show that the probability of treatment failure,
caused by resistant mutants, rises with the level of quiescence in
the context of therapy with two separate drugs (Figure 4b–d). This
is a direct consequence of the previous two sections. Let us
consider a colony consisting of wild-type and 1-hit mutant cells.
Let us ‘‘watch’’ the colony grow by tracking each of N-1 cell
divisions, see Figure 7. Whenever a cell division happens, it may be
a division of a cycling wild-type cell, or a division of a cycling 1-hit
mutant cell. It is only the latter process which in principle may lead
to the generation of two-drug resistance. The probability to create
a double mutant at each division is proportional to the probability
that a 1-hit mutant (and not a wild-type) cell divides. The number
of cycling wild-type cells in a colony of a given size is a decreasing
function of a , whereas the number of cycling 1-hit mutants is
independent of a (see the two previous paragraphs). Therefore, as
Figure 4. The probability of having no fully-resistant mutants at size N for different quiescence parameters. The numerical simulations are
performed according to the theory described in Text S1, Section 2.3. Each figure (a)–(d) shows the probability of no resistant mutants as a function of
b (the rate of cell awakening), for 10 different values of a (the rate at which cells become quiescent), a=0.1, 0.2, … and 1.0. (a) Treatment with m=1
drugs; all the curves corresponding to different values of a are the same. The parameters are N0=10
7 and u=10
27. (b) Treatment with m=2drugs,
N=10
11, u=10
27. (c) m=3drugs, N=10
13, u=10
26. (d) m=4drugs, N=10
13, u=10
25. In all plots, we took M0=10
3, l=1, d=0. The reason we used
different values of N and u for different values of m is because we chose the parameter regime corresponding to intermediate values of the
probability of treatment success. When this probability is nearly 100% or nearly 0, then the dependence on a and b is less apparent and less
meaningful.
doi:10.1371/journal.pone.0000990.g004
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increases. In other words, among all cycling cells, the percentage
of mutants increases with a, and so does the probability to create
2-hit mutants. Thus, the probability of resistance generation
against 2 drugs increases with quiescence parameters.
Generalizations These results can be generalized. First of all,
we can show by similar methods that the probability of mutant
generation increases with quiescence for 3- and higher-degree
mutants (Figure 4). In fact, the dependence becomes stronger for
larger numbers of drugs. However, we need to keep in mind that
the actual probability of resistance becomes lower the more drugs
we use, because it takes more mutation events to generate mutants
simultaneously resistant to several drugs. Finally, all the results
derived here apply for systems with a nonzero death rate, and
a nonzero rate of cell ‘‘awakening’’, b, see Text S1, Section 3.4.
Cell death and mutant generation–a comparison
In a previous paper, we examined the effect of cell death on the
probability of treatment failure as a result of acquired drug
resistance [41]. We found a very similar pattern. The probability
of treatment failure was independent of the death rate of tumor
cells in the context of therapy with a single drug, which was also
found in earlier studies by [43]. However, when treatment was
assumed to occur with two or more drugs, the probability of
treatment success depended on the death rate of tumor cells. The
higher the death rate of tumor cells relative to their division rate,
the higher the probability that mutant cells that are resistant
against all drugs induce failure of therapy. While this result is
identical to that observed for cellular quiescence, the reason for it
is different. It is explained in the remaining part of this section.
The probability of pre-existence of one-hit resistant
mutants is independent of the death rate The probability
of creating resistance before the start of treatment is defined by the
probability to have at least one 1-hit mutant at a given colony size,
which is given by (probability to create a mutant) x (probability for a mutant
clone to survive).The probability to create a mutant clone is
proportional to the number of cell divisions. In turn, the
number of cell divisions is a changing function of the death rate.
With a zero death rate it takes exactly N-1 cell divisions to go from
1 cell to N cells. As the death rate increases, it can take a lot more
cell divisions to expand, because cell divisions are (partially)
countered by cell deaths. Therefore, there are more cell divisions
for a larger death rate, and as a consequence, more 1-hit mutants
are produced. However, the probability for a mutant to survive is
a decreasing function of the death rate, which exactly compensates
the gain in the number of clones produced. Therefore, the
Figure 6. The expected number of one-hit mutants does not depend
on the presence of quiescence. (a) represents a colony with no
quiescence, and there is quiescence in (b). The white triangles depict
growing colonies of cells (cells with quiescence grow slower). The end
size is the same in both cases. Dark triangles represent growing mutant
clones inside the colonies. The total number of mutant colonies is the
same in both cases (the same number of cell divisions). The mutant
colonies in (b) have a longer time to grow, but at the same time they
grow slower. Therefore the resulting frequency of mutants is the same
in (a) and (b).
doi:10.1371/journal.pone.0000990.g006
Figure 7. A schematic illustrating the argument stating that the
probability to produce 2-hit mutants increases with quiescence. Each
rectangle represents a colony of cells. There are three moments of time
shown, first we have N=24, then N=48 and finally N=72. Circles
represent wild-type cells, and stars–one-hit mutants. Gray shading
denotes the state of quiescence for wild-type and mutant cells. In (a) we
assume no quiescence (a=0), whereas in (b) there is a probability to
become quiescent (with a=1/3). The number of cycling 1-hit mutants
(empty stars) is the same in (a) and (b ) for the same values of N. The
number of quiescent wild-type cells is given by the fraction a of all wild-
type cells (e.g. 1/3 in (b)). At each moment of time, one of the cycling
cells is picked for reproduction. We can see that the probability to pick
a 1-hit mutant is always higher in (b) than in (a), because the fraction of
cycling one-hit mutants increases as the tumor grows. Therefore, the
probability to create a 2-hit mutant is higher in (b).
doi:10.1371/journal.pone.0000990.g007
Figure 5. A schematic demonstrating the number of cell divisions
that is needed for a colony of cells to expand from 1 cell to N cells (in
the figure, N=6). Empty circles represent cycling cells, and gray circles
represent quiescent cells. Columns depict states of the colony in
consecutive moments of time. The changes are marked by arrows. Two
arrows stemming from one cell represent a cell division. A single arrow
represents either a cell becoming quiescent or a quiescent cell waking
up. (a) A colony without quiescence. (b) A colony with quiescence. In
both cases we can see that it takes exactly N-1=5 cell divisions to
expand to size N; however the process in (b) contains more ‘‘events’’.
doi:10.1371/journal.pone.0000990.g005
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death rate.
It is interesting to note that the number of one-hit mutants is
a growing function of both the death rate and the senescence rate,
but for different reasons. If we increase the death rate, the total
number of cell divisions to reach size N will increase, and so will
the number of mutants (but the average size of a clone size will
remain the same). If we increase a, the total number of divisions
will not change but the average clone size will grow, again leading
to an increase in the total mutant number.
The probability of pre-existence of two-hit resistant
mutants increases with the death rate While the
probability to have 1-hit mutants is independent of the death
rate, the average number of 1-hit mutants that are produced and
survive by the time the tumor size reaches size N is an increasing
function of the death rate. The reason is as follows. The mutants
are produced more often at higher death rates (because of the
increased total number of cell divisions). Thus, more mutants are
seeded to undergo clonal expansion. However, the size of the
mutant clones is independent of the death rate (in the same
manner as it was independent of the quiescence parameters, see
Fig. 4). Therefore, the total amount of 1-hit mutants present at size
N is an increasing function of the death rate. As a direct
consequence of this, the probability to have 2-hit mutants at size N
is also an increasing function of the death rate. This explains why
the likelihood of 2-drug resistance is a growing function of cell
death. This result can be extended to a larger number of drugs.
DISCUSSION
In this paper, we have examined the effect of cellular quiescence in
CML cells on the kinetics of the treatment response, and on the
chances that treatment fails because of the generation of drug
resistant mutants. This was done in the context of targeted therapy
using small molecule inhibitors. In accordance with experimental
data [29,30], we found a parameter region in which initiation of
treatment results first in a fast rate of CML cell decline, followed
by a second phase that is characterized by a slower rate of CML
cell decline. This is simply the consequence of the quiescence
dynamics. Note however, that this behavior is not expected to be
universal, since the model predicts alternative patterns of cell
decline in other parameter regions. The decline could occur in
a single phase with a single exponential rate of decline, or the first
phase of decline can be slower, followed by a faster phase (a
reverse biphasic decline). Whether these patterns can be observed
in experimental data requires the accumulation of more data sets
that document CML dynamics during drug therapy. In the
context of the biphasic decline that is also observed in data,
parameter combinations determine when the switch occurs to the
second and slower phase of treatment, and the expected time it
takes to drive the tumor cells extinct. If it takes too long to drive
the tumor cells extinct, the practical implication is that drug
treatment fails to eliminate the tumor. Variations in quiescence
parameters could determine whether CML relapses after pro-
longed treatment with imatinib, as observed in many cases [29–
32], or whether relapse does not occur, as observed in a small
subset of patients [33].
These notions add to previous theoretical work that examines
the decline of CML cells during therapy [29,30]. The paper by
Michor et al [29,30] explains the bi-phasic decline of CML cells by
a hypothesized differential susceptibility of CML cell subpopula-
tions to the drug imatinib. It is argued that differentiated cells are
readily attacked by the drug, while cancer stem cells are not
affected by treatment. The study by Roeder et al [29,30] also uses
mathematical arguments to address the bi-phasic decline of CML
cells during treatment. Their models included elements of
competition of cells in stem cell niches, and also invoked the
concept of cellular quiescence to account for the bi-phasic pattern
of cell decline. While the study by Roeder et al [29,30] also
includes the concept of cellular quiescence, our model is different
in nature, examines different questions, and is therefore com-
plentary. For example, our explanation of the two phases of CML
decline (one mainly driven by the eradication of cycling cells, and
the second one the awakening and death of quiescent cells) is very
different from the explanation proposed by Roeder et al [29,30].
Also, our paper examines the role of quiescence in drug resistance
generation in cancer, which is not discussed in the papers by
Roeder et al [29,30].
Overall, the mathematical models that take into account cellular
quiescenceintumor growthare based on earlier mathematicalwork.
In a series of papers [44–46], Gyllenberg and Webb examined the
role of cellular quiescence on the pattern of tumor growth. Using
ordinary differential equation models, they suggested that basic
Gompertzian tumor growth can be explained by a non-linear
phenomenon that arises from an increased probability for cells to
enterquiescenceat largertumorsizes[45].Thesedynamicsoftumor
growth have also been studied in the context of more complex age
and size structured population models [44,46] that revealed more
biologically interesting properties.
The second half of our paper investigates the effect of cellular
quiescence on the evolutionary dynamics of mutants that are
resistant against targeted drug therapies. In this respect, we found
that in the context of treatment with a single drug, quiescence
parameters do not influence the probability that drug resistant
mutants contribute to treatment failure. On the other hand, if the
cancer is treated with a combination of two or more drugs with
different targets, then increased quiescence promotes treatment
failure as a result of drug resistant mutants. However, while
cellular quiescence increases the time until the cancer cells are
reduced to low numbers or driven extinct, we find that this
prolonged treatment phase is irrelevant for the generation of drug
resistant mutants. Instead, if treatment fails because of the
presence of drug resistant mutants, then they will have evolved
during the tumor growth phase before treatment was initiated.
Thus, strategies aimed at shortening the treatment phase, for
example by activating quiescent cells, will not reduce the chances
that treatment fails as a result of drug resistance. Similarly, if the
tumor responds well to a given treatment regime, prolonged
therapy to prevent relapse will not increase the chances of
treatment failure as a result of drug resistance.
Our theoretical framework should be further validated in the
context of clinical studies. We have already shown that our model
can describe the observed bi-phasic decline of CML cells upon
therapy. The data plotted in Figure 3 hint that apart from the bi-
phasic decline, other patterns of CML dynamics during treatment
may be observed in clinical data, as suggested by our model. This
requires further investigation. Finally, it will be important to address
our result that quiescence contributes to the evolution of drug
resistance if patients are treated with two or more drugs in
combination. Apart from imatinib other targeted drugs are
becoming available for the treatment of CML [23,24,35]. According
to our model, variation in the outcome of treatment could be
explained by differences in the number of quiescent cells that have
been generated during tumor growth. This could be addressed by
examining the degree of cellular quiescence that is found in a tumor
before the start of treatment. Perhaps an experimentally simpler
strategy would be to perform in vitro experiments, in which a tumor
cell population is allowed to grow towards a certain size, after which
it is treated with a combination of two or more drugs. This could
Quiescence and CML Therapy
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resistance, and correlate this with the amount of cellular quiescence
found in the cell culture.
MATERIALS AND METHODS
Here, we describe our general modeling approaches. Further
mathematical details and calculations are found in the Supple-
mentary Information ( Text S1).
Stochastic modeling
In order to study the dynamics of a cell population with quiescence,
we use a stochastic modeling approach. Namely, we formulate
a continuous time, discrete state-space birth-death process (with or
without mutations), where the rates of cell divisions and cell death
are l and d respectively, and where cells enter the state of quiescence
with a rate a and wake up from quiescence with a rate b.T h e
resulting linear 2-dimensional Markov process corresponds to the
exponential distribution of the timing of various elementary events
(such as cell divisions, death etc).
Combinatorial mutation network
We model the generation of resistance as mutation events. In
order to acquire resistance to one drug, a cell must gain one
mutational hit. Cells resistant to two drugs are double-hit mutants,
etc. We assume that there is no cross-resistance in the system, such
that each mutation event gives rise to resistance to one drug, and
not to the other drugs. All the (partially and fully) resistant types
can be placed on a combinatorial mutation network. The structure
of the couplings between the equations is read off from such
a network.
Pre-treatment and treatment regimes
We assume that before treatment starts, all cells satisfy l.d, that is,
the division rate is larger than their death rate. For our
calculations, we also assume that all the mutants are neutral
before the beginning of therapy. This assumption is not a necessity
and the general model allows for positively- and negatively-
selected mutants. We model the treatment phase by assuming that
susceptible and partially-resistant mutants are killed by the drugs,
such that their death rate is larger than their division rate. The
opposite is true for the fully-resistant phenotype. By using standard
methods, we write down the Kolmogorov forward equation for the
probabilities. The coefficients in this equations (the rate constants
of all the processes) are different depending on whether we
consider the pre-treatment phase or the treatment phase. From
this point, we proceed in two different ways, described in the
following two sections.
Equations for the averages
We formulate ordinary differential equations (ODEs) for the first
moments (the expected numbers of cycling and quiescent cells) and
study their behavior. This is done both in the absence of mutations
(to study cancer development and treatment without resistance)
and in the presence of mutations (to study cancer development and
treatment in the face of emerging resistant mutants). The ODEs
are linear with constant coefficients, and exact analytical solutions
are possible. These solutions are not always transparent, especially
in the case of multiple drug treatments. To understand the
behavior, we find approximations for various modes of growth and
decay, and study relevant limiting cases.
Probability generating function
We also derive a partial differential equation (PDE) for the
probability generating function. Probability generating function is
used to study the probability of colony extinction, probability of
treatment success, and the probability of having resistant mutants
at a given colony size. All these quantities are obtained by solving
the PDE by using the method of characteristics, because the PDE
is of a transport type. The solutions are calculated numerically, for
a subset of parameters values. Their behavior is also studied
analytically by looking at the ODEs for the characteristics, and
analyzing various limits of the exact solution, as well as their fixed
points.
SUPPORTING INFORMATION
Text S1
Found at: doi:10.1371/journal.pone.0000990.s001 (0.15 MB
PDF)
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